TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a m
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-23 3:05 AM EDT | TempraMed Technologies Ltd.
Unbuzzd Wellness Announces Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, the scientifically proven beverage formulated to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, announces that it completed the consolidation of its issued and outstanding common shares on the basis of one post-consolidation common share for every 24 pre-consolidation common shares, effective September
2026-09-22 7:24 PM EDT | Unbuzzd Wellness Inc.
Early Warning Press Release - FirstLine Venture Partners Corporation Announces Acquisition of Securities of Forward Water Technologies Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - FirstLine Venture Partners Corporation ("FirstLine") announces that, on September 9, 2026, it acquired an aggregate of 150 units (the "Units") of Forward Water Technologies Corp. (TSXV: FWTC) ("FWTC" or the "Issuer") at a price of $1,000 per Unit, for aggregate consideration of $150,000, pursuant to FWTC's non-brokered private placement of Units for aggregate gross proceeds of $150,000 (the "Ac
2026-09-22 6:16 PM EDT | FirstLine Venture Partners Corporation
DIMERx Secures Second NIH Award to Advance DMX-201 for Sickle Cell Disease
San Francisco, California--(Newsfile Corp. - September 22, 2026) - DIMERx, Inc., a clinical-stage biopharmaceutical company developing novel dimer-based therapeutics, today announced that it has received a Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) to advance DMX-201 for sickle cell disease (SCD). DMX-201 has the potential to become a first-line therapy for acute chest syndrome (ACS), helping reduce acute respiratory distress, sh
Biotechnology, Pharmaceuticals, Health
2026-09-22 9:00 AM EDT | DIMERx INC.
Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products
Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand. Management estimates that Adi
Healthcare and Hospitals, Health
2026-09-22 8:00 AM EDT | Adia Med Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
Toronto, Ontario--(Newsfile Corp. - September 22, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion"
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-22 7:33 AM EDT | Rhelion Life Sciences Corp.
Promino Reports Strength in Revenue as New Inventory and Kroger Distribution Drive Growth
Burlington, Ontario--(Newsfile Corp. - September 22, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") today reported preliminary, unaudited net revenue of approximately C$198,500 for August 2026. With cost of revenues of approximately C$70,200, positive gross profit margins were achieved. August represented an acceleration in revenues and gross margins as the Company returned to inventory following product constr
Food / Beverages, Sports, Health
2026-09-22 7:00 AM EDT | Promino Nutritional Sciences, Inc.
WELL Health Launches WELL Research, an End-to-End Clinical Trial Platform Built on Canada's Largest Outpatient Network
WELL Research is the clinical research brand of WELL Health Technologies. WELL Research offers the unique combination of full-service contract research organization (CRO) services in early-phase trials, site management organization (SMO) execution at late-stage trial sites, and bioanalytical services across every phase of clinical trials. Together, these capabilities span the full clinical trial value chain and allow sponsors and providers to enrol the righ
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-22 6:00 AM EDT | WELL Health Technologies Corp.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization adv
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-21 7:49 AM EDT | Rhelion Life Sciences Corp.
NuGen Announces Loan Agreement with Sol-Millennium Medical HK Limited
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce the entering into of a loan agreement (the "Loan Agreement") dated September 18, 2026 with Sol-Millennium Medical HK Limited (the "Lender") in the amount of up to C$1.3 million (the "Loan"). The initial advance under the Loan Agreement will be provided to the Company in the amount of C$500,000 following confirma
Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-21 7:42 AM EDT | NuGen Medical Devices Inc.
naia Relief Inc. Announces Launch of naia 24/7 Mind Mentor Through Strategic Partnership with Felix Global
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - naia Relief Inc. (TSXV: NAIA) ("naia Relief" or the "Company") is pleased to announce the launch of naia, its 24/7, 365-day mind mentor and well-being and performance platform, through a strategic partnership with Felix Global, a leading global talent and organizational solutions provider. The partnership represents an important milestone in naia Relief Inc.'s global commercialization strategy, providing organiza
2026-09-21 7:00 AM EDT | Naia Relief Inc.
QScreen AI Announces $681,000 Debt Settlement with Directors and Officers
Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen", "QAI" or the "Company"), an innovator in physiological AI screening and developer of an intelligence platform for clinical and occupational health applications, is pleased to announce that it has agreed to settle an aggregate of $681,000 of indebtedness owing to certain directors and officers of the Company (the "Debt Settlement") through the issuance of approximately
2026-09-21 6:14 AM EDT | QScreen AI Inc.
Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice
Dublin, Ireland--(Newsfile Corp. - September 21, 2026) - Cosmo N.V. (SIX: CMHC) (FSE: C43) ("Cosmo") today announced the results from its CADeNCE study. The study, led by Dominitz et al. and published in Gastroenterology, is the largest cluster-randomised quality improvement study of computer-aided detection (CADe) in colonoscopy. It analysed more than 334,000 procedures performed under routine clinical conditions by 816 endoscopists across 139 U.S. Veterans Health Ad
Healthcare and Hospitals, Health
2026-09-21 1:07 AM EDT | Cosmo Pharmaceuticals N.V.
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance. The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in T
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-18 4:45 PM EDT | TempraMed Technologies Ltd.
Unbuzzd Wellness Announces Resignation of Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, the scientifically proven beverage formulated to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, announces that Richard Buzbuzian will resign from his position as Chief Executive Officer of the Company, effective October 1, 2026. The Company thanks Mr. Buzbuzian for his contributions and wishes him
2026-09-17 6:25 PM EDT | Unbuzzd Wellness Inc.
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together wit
2026-09-17 10:41 AM EDT | BetterLife Pharma Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
Toronto, Ontario--(Newsfile Corp. - September 17, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly ow
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-17 7:52 AM EDT | Rhelion Life Sciences Corp.
Altrova Health Announces Proposed Debt Settlement
Toronto, Ontario--(Newsfile Corp. - September 16, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") announces that it proposes to enter into debt settlement agreements with three consultants to settle aggregate indebtedness of C$215,000 through the issuance of an aggregate of 3,583,333 comm
2026-09-16 7:07 AM EDT | Altrova Health Inc.
Rise Nano Optics to Attend the Vision Council's 2026 Lab Leadership Forum
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that the Company
2026-09-16 7:00 AM EDT | Rise Nano Optics Ltd.
CBD of Denver, Inc. (CBDD) Signs Definitive Share Exchange Agreement with BioCannabis M. IKE, Advancing Strategic Merger Toward Completion
Denver, Colorado--(Newsfile Corp. - September 15, 2026) - CBD of Denver, Inc. (OTCID: CBDD) ("CBDD" or the "Company") today announced that it has entered into a definitive Share Exchange Agreement with BioCannabis M. IKE ("BioCannabis"), a Greece-based company operating in the health and wellness sector. The agreement follows the Letter of Intent previously announced by the parties and the completion of CBDD's due diligence review. Following its review of BioCannabis' business, operatio
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-09-15 9:00 AM EDT | CBD of Denver Inc.